Data Published in BMC Veterinary Research shows that OKV-119 exenatide implant reduced feline weight
Felines share many pathophysiologic obesity phenotypes with humans, further supporting clinical.
Vivani Medical announced proof-of-concept data for a subdermal exenatide implant designed for feline obesity and diabetes, which was published in BMC Veterinary Research.
Vivani Medical, Inc. (VANI) Tuesday announced positive proof-of-concept weight loss data with OKV-119, a miniature, subdermal, exenatide drug implant designed to treat feline obesity and diabetes.
Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act.